Latest News | Dr Reddy's Re-launches Naproxen Sodium OTC Tablets in US Market
Get latest articles and stories on Latest News at LatestLY. Dr Reddy's Laboratories Ltd on Tuesday announced the re-launch of over-the-counter (OTC) Naproxen Sodium Tablets USP, 220 mg, the store-brand equivalent of Aleve, in the US market, as approved by the US Food and Drug Administration (USFDA).
Hyderabad, Aug 3 (PTI) Dr Reddy's Laboratories Ltd on Tuesday announced the re-launch of over-the-counter (OTC) Naproxen Sodium Tablets USP, 220 mg, the store-brand equivalent of Aleve, in the US market, as approved by the US Food and Drug Administration (USFDA).
"The launch of Dr Reddys NaproxenSodium Tablets, 220 mg (OTC), isan important addition to our Pain/Analgesics portfolio of OTC products.
This launch represents our continued endeavour to leverage our strong capabilities and vertically integrated supply chain on key APIs like naproxen to ensure a consistent and reliable supply of finished products for our customers and patients," Marc Kikuchi, CEO, North America Generics, Dr Reddys Laboratories said.
Dr Reddys OTC Naproxen Sodium Tablets USP, 220 mg is an over-the-counter non-steroidal anti-inflammatory drug (NSAID) for use as a pain reliever and fever reducer.
Naproxen Sodium Tablets USP, 220 mg, had US retail sales of approximately USD 316 million as of July 2021, Dr Reddys said quoting market figures. Dr Reddys Naproxen Sodium Tablets USP, 220 mg, will be available in multiple-pack sizes to allow consumers a variety of purchasing options.
Aleveis a trademark of Bayer HealthCare LLC.
(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)